Osteoarthritis Breakfast Briefing – Day 6

November 11, 2020
Abstract Number: 1643
Schnitzer T, Berenbaum F, Davignon I, et al.
Evaluating Analgesic Response to Subcutaneous Tanezumabin Patients with Inadequate Treatment Response to Other Analgesics Based on Daily E-pain Diaries:
A Pooled Analysis of 2 Randomized, Placebo-controlled Studies

 

Osteoarthritis Breakfast Briefing – Day 5

November 10, 2020
Abstract Number: 1641
Hunter D, Neogi T, Churchill M, et al.
Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab:
Results from a 56-Week Randomized NSAID-Controlled Study

 

Osteoarthritis Breakfast Briefing – Day 4

November 9, 2020
Abstract Number: 1640
Schnitzer T, Berenbaum F, Conaghan PG, et al.
Clinically Important Improvement in Osteoarthritis Pain at Week 16 After Subcutaneous Administration of Tanezumab:
Pooled Analysis from International Studies

 

Osteoarthritis Breakfast Briefing – Day 3

November 8, 2020
Abstract Number: 1482
Carrino J, McAlindon T, Vigno E, et al.
Joint Safety with Tanezumab: Integrated Analyses from Randomized Controlled Phase 3 Studies in Patients with Osteoarthritis

 

Osteoarthritis Breakfast Briefing – Day 2

November 7, 2020
Abstract Number: 0708
Denise Baldock and Casey Zhang
Differences in Treating Knee Osteoarthritis by Clinician Specialty

 

Osteoarthritis Breakfast Briefing – Day 1

November 6, 2020
Abstract Number: 0140
Conaghan PG, Dworkin R, Schnitzer T, et al.
Meaningful Within-Patient Change in WOMAC Domains in Patients with Moderate-to-Severe Osteoarthritis